Kadimastem - Stem Cell to Cure Diseases

Drug Discovery > Diabetes

Kadimastem's Diabetes Program  

Kadimastem's cell therapy to treat diabetes is based on stepwise differentiation of hPSC towards pancreatic islet-like clusters, producing functional insulin (beta cells), glucagon (alpha cells) and other hormones. Starting from large scale hPSC cultures, Kadimastem's process drives the cells through several condition changes towards pancreatic endocrine cells. These functional hormones producing cell aggregates will be encapsulated to prevent immune rejection and mobility in the patient body, while allowing glucose sensing and insulin secretion.

Developmental stage

Using an unlimited cell source, hPSCs, we apply a stepwise differentiation protocol to produce islet-like clusters containing >50% insulin producing cells (β-cells) and about 20% glucagon producing cells (α-cells). Our in-vivo experiments have demonstrated functionality of the cells manifested by secretion of therapeutic levels of human insulin. The cells are encapsulated to prevent immune rejection and to contain the cells and prevent their mobility in the patient's body, while allowing glucose sensing and insulin secretion. Kadimastem’s therapy will be a cell containing off-the-shelf product that will be administered subcutaneously.

Potential Market

There are approximately 158 million relevant diabetes patients worldwide today1. The American Diabetes Association (ADA) estimated the total costs of diagnosed diabetes to be $245 billion annually (in the US) including $176 billion in direct medical costs and $69 billion in reduced productivity2. The global cost is estimated to be $548 billion annually and will grow to about $727 billion annually by 20353.

 

References:
1. http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures
2. http://www.diabetes.org/advocacy/news-events/cost-of-diabetes.html
3. http://www.diabetesatlas.org/key-messages.html ; http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav